Evidence map›Paper›PMID 33825976›Full record

ArticleHeart and vessels2021

Prognostic ability of mid-term worsening renal function after percutaneous coronary intervention: findings from the SHINANO registry.

Yoshiteru Okina, Takashi Miura, Keisuke Senda, Minami Taki, Masanori Kobayashi, Masafumi Kanai, Yukari Okuma, Takashi Yanagisawa, Naoto Hashizume, Kyuhachi Otagiri and 21 more

Open access · hybridAbstract read
In one paragraph

Article in Heart and vessels, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 11 institutions in 1 country.

Yoshiteru OkinaDepartment of Cardiology, Nagano Municipal Hospital, 1333-1 Tomitake, Nagano, 381-0006, Japan. xxv0w0v.1k8.96@gmail.com.ORCID http://orcid.org/0000-0002-4134-1915
Takashi MiuraDepartment of Cardiology, Nagano Municipal Hospital, 1333-1 Tomitake, Nagano, 381-0006, Japan.
Keisuke SendaDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Nagano, Japan.
Minami TakiDepartment of Cardiology, Shinshu Ueda Medical Center, Ueda, Japan.
Masanori KobayashiDepartment of Cardiology, Matsumoto Kyoritsu Hospital, Matsumoto, Japan.
Masafumi KanaiDepartment of Cardiology, Nagano Red Cross Hospital, Nagano, Japan.
Yukari OkumaEpartment of Cardiology, Suwa Red Cross Hospital, Suwa, Japan.
Takashi YanagisawaDepartment of Cardiology, Saku Central Hospital, Saku, Japan.
Naoto HashizumeDepartment of Cardiology, Shinonoi General Hospital, Nagano, Japan.
Kyuhachi OtagiriDepartment of Cardiology, Ina Central Hospital, Ina, Japan.
Kyoko ShoinDepartment of Cardiology, Aizawa Hospital, Matsumoto, Japan.
Noboru WatanabeDepartment of Cardiology, Hokushin General Hospital, Nagano, Japan.
Soichiro EbisawaDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Nagano, Japan.
Kenichi KarubeDepartment of Cardiology, Okaya Municipal Hospital, Okaya, Japan.
Hiroyuki NakajimaDepartment of Cardiology, Matsushiro General Hospital, Nagano, Japan.
Tatsuya SaigusaDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Nagano, Japan.
Yusuke MiyashitaDepartment of Cardiology, Nagano Red Cross Hospital, Nagano, Japan.
Daisuke KashiwagiDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Nagano, Japan.
Keisuke MachidaDepartment of Cardiology, Ina Central Hospital, Ina, Japan.
Naoyuki AbeDepartment of Cardiology, Nagano Red Cross Hospital, Nagano, Japan.
Takahiro TachibanaDepartment of Cardiology, Saku Central Hospital, Saku, Japan.
Yusuke KanzakiDepartment of Cardiology, Shinonoi General Hospital, Nagano, Japan.
Takuya MaruyamaDepartment of Cardiology, Shinonoi General Hospital, Nagano, Japan.
Hidetomo NomiDepartment of Cardiology, Saku Central Hospital, Saku, Japan.
Takahiro SakaiDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Nagano, Japan.
Hisanori YuiDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Nagano, Japan.
Tomoaki MochidomeDepartment of Cardiology, Nagano Municipal Hospital, 1333-1 Tomitake, Nagano, 381-0006, Japan.
Takahiro KobayashiDepartment of Cardiology, Nagano Municipal Hospital, 1333-1 Tomitake, Nagano, 381-0006, Japan.
Toshio KasaiDepartment of Cardiology, Nagano Municipal Hospital, 1333-1 Tomitake, Nagano, 381-0006, Japan.
Uichi IkedaDepartment of Cardiology, Nagano Municipal Hospital, 1333-1 Tomitake, Nagano, 381-0006, Japan.
Koichiro KuwaharaDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Nagano, Japan.
Shinshu University · JPNagano Municipal Hospital · JPNagano Red Cross Hospital · JPSaku Central Hospital · JPShinonoi General Hospital · JPAizawa Hospital · JPHokushin General Hospital · JPKameda Medical Center · JPMatsumoto City Hospital · JPNagano Matsushiro General Hospital · JPSuwa Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease is a prognostic factor for cardiovascular disease. Worsening renal function (WRF), specifically, is an important predictor of mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI). We evaluate the prognostic impact of mid-term WRF after PCI on future cardiovascular events. We examined the renal function data of 1086 patients in the first year after PCI using the SHINANO 5-year registry. Patients were divided into two groups, mid-term WRF and non-mid-term WRF, and primary outcomes were major adverse cardiovascular events (MACE) and death. Mid-term WRF was defined as an increase in creatinine (≥ 0.3 mg/dL) in the first year after PCI. Mid-term WRF was found in 101 patients (9.3%), and compared to non-mid-term WRF, it significantly increased the incidence of MACE (p < 0.001), and all-cause death (p < 0.001), myocardial infarction (p = 0.001). Furthermore, mid-term WRF patients had higher incidence of future heart failure (p < 0.001) and new-onset atrial fibrillation (p = 0.01). Patients with both mid-term WRF and chronic kidney disease had increased MACE compared to patients with either condition alone (p < 0.001). Similarly, patients with mid-term WRF and acute kidney injury had increased MACE compared to patients with either condition alone (p < 0.001). Multivariate Cox regression analysis revealed mid-term WRF as a strong predictor of MACE (hazard ratio: 2.50, 95% confidence interval 1.57-3.98, p < 0.001). Mid-term WRF after PCI negatively affects MACE, as well as future admission due to heart failure and new-onset atrial fibrillation, chronic kidney disease, and acute kidney injury.

Indexed as

Acute Kidney InjuryPercutaneous Coronary InterventionRenal Insufficiency, ChronicAtrial FibrillationHeart FailureHumansKidneyMyocardial InfarctionPrognosisRegistriesCoronary vascular diseaseMajor adverse cardiovascular event (MACE)Prognostic factorRenal insufficiency

Identifiers

PMID33825976
PMCPMC8379120
OpenAlexW3147214403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.